/ /

  • linkedin
  • Increase Font
  • Sharebar

    Aflibercept for DME effective therapy in VISTA, VIVID trials

    Phase III data show durable visual acuity gains through 2 years; global study may provide more insight

     

    TAKE HOME:

    Data from the phase III VISTA-DME trial show aflibercept 2 mg every 4 or every 8 weeks remains superior to laser photocoagulation and is associated with stable improvements in best-corrected visual acuity and macular thickness.

     

     

    Houston—Ongoing treatment of diabetic macular edema (DME) with intravitreal aflibercept 2 mg (Eylea, Regeneron) at 4- or 8-week intervals (2q4 or 2q8) is associated with sustained functional and anatomic benefit during follow-up approaching 2 years, according to data from the U.S. phase III VISTA-DME trial.

    “These data indicate aflibercept is a very effective treatment for DME, and the most encouraging aspect of the findings is that eyes receiving injections every other month maintained excellent visual acuity gains through 2 years,” said David M. Brown, MD, retinal specialist at Retina Consultants of Houston and Houston Methodist Hospital.

    In case you missed it: Aflibercept acuity gains rival laser for BRVO

    “If the 2q8 regimen is undertreating the disease, we would expect to see the benefit decline as the treatment duration increases,” Dr. Brown said. “However, there was little change in the BCVA improvement between 1 and 2 years, suggesting that every other month injections with aflibercept after an initial loading course might be sufficient for the average patient needing treatment for DME.”

     

    NEXT: More about VISTA-DME

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results